The top five antidyslipidemic brands: Lipitor (atorvastatin, Pfizer), Crestor (rosuvastatin, AstraZeneca), Zetia (ezetimibe, Merck), Vytorin (simvastatin and ezetimibe, Merck) and Tricor (fenofibrate, Solvay, Abbott) accounted for 74% of the market in 2009. By the end of 2019, the share commanded by these top five brands in the antidyslipidemic market is expected to fall to 35% due to the impact of generics, which will themselves account for 39% of revenues in 2019.
This drop in value of the dominant brands will take a lot of the value in the market with it. Overall sales value across the seven major markets is expected to drop from $26.6 billion in 2009 down to $17 billion in 2019.
Gideon Heap, healthcare analyst at Datamonitor, comments: “The antidyslipidemic market has been performing well over the last three years. It has shown steady growth, driven by an acceleration of Crestor (rosuvastatin, AstraZeneca) sales following positive JUPITER trial results and subsequent approval in a new preventative indication.
“This growth will end by 2012 after the crucial patent expiry of Pfizer’s Lipitor in the US, which will send the drug’s revenue into sharp decline and fuel the continuing genericisation of the market.”
Whilst the Datamonitor report identifies some innovative agents in the late-stage pipeline, it suggests they will face significant challenges in gaining a firm foothold in the overcrowded antidyslipidemic market.
Gideon concludes: “Ever tightening approval regulations and the safety concerns surrounding marketed products such as Vytorin will be major barriers for innovative agents, suggesting that the era of mega blockbuster antidyslipidemics, once over, will not return.”
Gideon Heap is available for comment. To arrange an interview or for further details regarding this release please contact Joe Dixon in the Datamonitor press office on + 44 (0)161 238 4083, or email jdixon@datamonitor.com
ABOUT DATAMONITOR
The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world’s leading companies in making better strategic and operational decisions.
